Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report

PURPOSE: The purpose of this study was to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of vorinostat administered as a single agent and in combination 13-cis retinoic acid (13cRA) in children with refractory solid tumors; to evaluate the tolerabili...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Fouladi, Maryam, Park, Julie R., Stewart, Clinton F., Gilbertson, Richard J., Schaiquevich, Paula, Sun, Junfeng, Reid, Joel M., Ames, Matthew M., Speights, Roseanne, Ingle, Ashish M., Zwiebel, James, Blaney, Susan M., Adamson, Peter C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2010
Gaiak:
Original Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917318/
https://ncbi.nlm.nih.gov/pubmed/20606092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.9119
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak